Universal access to direct-acting antivirals (DAAs) may have led to the low prevalence of hepatitis C viraemia among people living with HIV (PLHIV) in The Netherlands, according to a study presented at IAS 2021.
In the 96-week interim analysis of the phase III BRIGHTE study presented at IAS 2021, the gp120 attachment inhibitor fostemsavir showed favourable safety and tolerability, and yielded strong rates of virologic response in heavily treatment-experienced (HTE) adults infected with extensive multidrug-resistant (MDR) HIV-1.
The combined regimen of bedaquiline, pretomanid, and linezolid (BPaL) may help treat highly drug-resistant tuberculosis (TB), even with lower doses or shorter treatment duration of linezolid, according to results of the phase III ZeNix trial presented at IAS 2021.
Treatment with the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) leads to sustained viral suppression through 4 years with no treatment-emergent resistance in treatment-naïve people living with HIV (PWH), according to a long-term study presented at IAS 2021.
The risk of contracting Trichomonas vaginalis (TV) infection seems to be higher in women using copper intrauterine devices (Cu-IUD) as a contraceptive, according to a study presented at the recently concluded 2021 International AIDS Society Conference on HIV Science (IAS 2021).
About four-fifths of heavily treated HIV patients with multidrug resistance have achieved viral suppression with the investigational long-acting subcutaneous lenacapavir (LEN) used in combination with an optimized antiretroviral (ART) regimen, according to the 26-week data from the ongoing phase II/III CAPELLA study.
The monthly dapivirine vaginal ring (DVR), which has been found to reduce HIV risk with no safety issues, continues to show its potential as an acceptable and safe preventive method against HIV, according to data from several phase III MTN* studies presented at IAS 2021.
Despite having depressive symptoms, treatment initiation rates seem to be improving among patients coinfected with HIV and hepatitis C virus (HCV), according to a study presented at the recently concluded 2021 International AIDS Society Conference on HIV Science (IAS 2021).
Use of feminizing hormone therapy (FHT) does not appear to cancel the effect of oral pre-exposure prophylaxis (PrEP) in transgender women at high risk of HIV, according to data from the PrEParadas study presented at the 11th International AIDS Society Conference (IAS 2021).
Use of pre-exposure prophylaxis (PrEP) is extremely low among gay, bisexual, and other men who have sex with men (GBM) in five Asian countries, reveals a study presented at the 11th International AIDS Society Conference (IAS 2021).